NCT06431594

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 385 (estimated)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.

Conditions

• Solid Tumors
• Neoplasms

Interventions

Type	Name	Description
DRUG	GSK5733584	GSK5733584 will be administered

Timeline

• Start date: 2024-07-02
• Primary completion: 2027-02-01
• Completion: 2027-09-20
• First posted: 2024-05-28
• Last updated: 2025-06-25

Locations

47 sites across 14 countries: United States, Argentina, Australia, Belgium, Canada, Finland, France, Italy, Japan, Netherlands, South Korea, Spain, Sweden, United Kingdom

Regulatory

• FDA-regulated drug study